
- Danish stocks
- Norwegian stocks
- Swedish stocks
- AktieTorget
- A1M Pharma
- Accelerator Nordic
- AlphaHelix
- AroCell
- Biotech-IgG
- Brighter
- Clinical Laserthermia
- Emotra
- Enzymtica
- Eurocine Vaccines
- European Inst. of Science
- IDL Biotech
- Medfield Diagnostics
- MedicPen
- MediRox
- MediRätt
- Micropos Medical
- PharmaLundensis
- Respiratorius
- Rubicon Life Science
- SensoDetect
- WntResearch
- Orasolv
- Senzime
- SPAGO Imaging
- Vivoline Medical
- First North Stockholm
- OMX Stockholm A-F
- OMX Stockholm G-Z
- AktieTorget
- US stocks
- General discussion
- All posts
It is… if it didn't cost a fortune in patent-attorney fees. Lets hope that EPO makes Abbott pick up the check.
It wouldn't be the first time:
http://en.wikipedia.org/wiki/Opposition_procedure…
the VERY same Abbott that threatened EPO/BioPorto if BioPorto did not present their data in due time 🙂 Its almost hillarious…
This leaves BioPorto with at least two options – either to ask EPO to declare the papers unadmissable, or – at that might be a sign of strenght, let them present the material in spite…